Anatomic Stage III Breast Cancer AJCC v8 Clinical Trial
— E-PROOFOfficial title:
E-PROOF: E-Intervention for Protein Intake and Resistance Training to Optimize Function
This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-years old) cancer survivors. Declines in adequate protein and calorie intake results in faster loss of muscle mass and physical functioning in older adults. A novel approach to improving physical function in older cancer survivors (OCS) is to utilize online, tailored education and counseling from registered dietitians and exercise scientists, to improve dietary intake (protein intake, diet quality) and participation in resistance exercise. The purpose of this study is to help researchers learn whether an online dietary and resistance training intervention improves diet, exercise, physical function, and health outcomes in OCS.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | May 15, 2025 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - >= 65 years of age - A primary diagnosis of stage I-III breast, colorectal, and prostate cancer - Completion of primary curative treatment - Reported at least 1 physical function limitation on the RAND-36 Physical Function Subscale (PFSS) ("limited a little", "limited a lot") - No evidence of progressive disease or second cancers - Community-dwelling - Able to provide consent Exclusion Criteria: - Currently receive cancer treatment (e.g., chemotherapy, radiation) - Have liver and/or renal disease limiting their protein intake - Are under the care of a Registered Dietician (RD)/nutritionist - Participating in other diet/exercise interventions - Consume protein supplements - Have contraindications to unsupervised exercise (e.g., walker/wheelchair use) |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical function | Measured by the Short Physical Performance Battery (SPPB) score. Efficacy will be based on 12 weeks. The SPPB score is a continuous variable, collected as the total score ranging from 0-12. Group differences in SPPB scores over the time will be tested using repeated measures analysis of variance. Using the planned contrasts command, we will investigate the changes in SPPB scores within each group, and between the intervention and control groups at end-of-study. Descriptive statistics and frequency distributions will be used to characterize the sample. To examine the effect of the intervention on the changes in physical function, a linear mixed effect model will be adopted. | Up to 12 weeks post study completion | |
Secondary | Satisfaction of the delivery method and information provided by nutrition and exercise counseling sessions | Percentage of participant satisfaction ("satisfied" and "very satisfied") measured by a 5-item Likert-scale questionnaire | At 12 weeks | |
Secondary | Study accrual rate | Will be calculated by dividing the number of potential participants that passed screening by the total number of participants started in the study after appropriate informed consent procedures. | Up to 9 months | |
Secondary | Study retention rate | Will be calculated by dividing the total number of participants initiated by total number of participants in the study. Retention goal for this trial is 80%. If 80% (56/70) of participants are retained at end-of-study, the retention goal for this trial will be achieved. Overall retention rates and associated 95% confidence intervals will be reported. | At baseline and 12 weeks | |
Secondary | Study adherence rate | Participants will be determined to be adherent if they attend >= 80% of the intervention sessions (in-person meetings with study staff and online intervention sessions). Overall adherence rates and associated 95% confidence intervals will be reported. | At baseline, 12 weeks, and 3-month follow-up | |
Secondary | Muscle strength | Handgrip strength will be measured in both hands using a hydraulic grip strength dynamometer. Change in participant outcome measures from baseline to end-of-study will be assessed in kilograms at the baseline and end of study visits. | At baseline, 12 weeks, and 3-month follow-up | |
Secondary | Dietary quality and protein intake | Protein intake and dietary quality will be assessed by the National Cancer Institute's Diet History Questionnaire III using the Healthy Eating Index score ranging 0-100, with higher scores meaning higher diet quality. Change in participant outcome measures from baseline to end-of-study will be assessed using the Healthy Eating Index score. | At baseline and 12 weeks | |
Secondary | Resistance exercises | Self-reported resistance exercise will be assessed using the revised version of The Godin-Shephard Leisure-Time Exercise Questionnaire modified to specifically capture self-reported resistance exercise participation, reported in frequency of days per week and duration in minutes. Change in participant outcome measures from baseline to end-of-study will be assessed using the reported frequency of days per week and duration in minutes. | At baseline and 12 weeks | |
Secondary | Health-related quality of life (HRQoL) physical and emotional health scores | RAND-36 Health Status Measure is comprised of 36 items which automatically create 8 subscales assessing multiple aspects of HRQoL. Physical and mental component summaries are created. All scores range from 0-100, with 100 as the highest. Change in participant outcome measures from baseline to end-of-study will be assessed using the RAND-36 Health Status Measure score. | At baseline and 12 weeks | |
Secondary | Self-efficacy for improving diet quality and increasing resistance training | Self-efficacy will be measured via a 0-10 confidence scale rating the confidence of making exercise and diet changes, with 0 meaning not confident, 10 meaning very confident. Change in participant outcome measures from baseline to end-of-study will be assessed using the confidence scale rating. | At baseline and 12 weeks | |
Secondary | Technology competency | The 8-item eHealth Literacy Scale will measure knowledge, comfort, and perceived skills of engaging in eHealth at baseline and end-of-study. A 5-point Likert scale will be used. Change in participant outcome measures from baseline to end-of-study will be assessed using the 5-point Likert scale score. | At baseline and 12 weeks | |
Secondary | Anthropometry body weight in kilograms | Change in participant outcome measure body weight from baseline to end-of-study will be assessed using body weight in kilograms. | At baseline and 12 weeks | |
Secondary | Anthropometry height in inches | Change in participant outcome measure height from baseline to end-of-study will be assessed using height in inches. | At baseline and 12 weeks | |
Secondary | Anthropometry measuring waist circumference in centimeters | Change in participant outcome measure waist circumference from baseline to end-of-study will be assessed using waist circumference in centimeters. | At baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05673200 -
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03218826 -
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Completed |
NCT04535323 -
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05464810 -
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT04249622 -
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT03666819 -
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT05930483 -
Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT04862585 -
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05967286 -
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT04593277 -
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
|
N/A | |
Active, not recruiting |
NCT05086731 -
Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
|
N/A | |
Recruiting |
NCT05368428 -
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
|
N/A | |
Recruiting |
NCT04673448 -
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05539365 -
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04086875 -
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
|
N/A | |
Completed |
NCT00507923 -
Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer
|
N/A | |
Recruiting |
NCT06058377 -
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Recruiting |
NCT05455658 -
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05674578 -
Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors
|
N/A |